Clinical Trials
30 trialsVaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
National Cancer Institute (NCI)
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Rutgers, The State University of New Jersey
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Memorial Sloan Kettering Cancer Center
Pyroxamide in Treating Patients With Advanced Cancer
Memorial Sloan Kettering Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
BCX-1777 in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
Combination Chemotherapy in Treating Patients With Advanced Cancer
NYU Langone Health
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
University of Arizona
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Rutgers, The State University of New Jersey